{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:56:51Z","timestamp":1791212211435,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multisystem Inflammatory Syndrome in Children (MIS-C) is a hyperinflammatory condition with multi-organ involvement, particularly affecting the cardiac and gastrointestinal systems. Although immunomodulatory therapy is standard, treatment approaches vary. This study aimed to evaluate treatment modalities in MIS-C such as methylprednisolone (MP), intravenous immunoglobulin (IVIG), anakinra and therapeutic plasma exchange (TPE) based on clinical severity and laboratory parameters in a prospectively followed cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 125 MIS-C patients were included in the study and followed for at least 6 months after discharge. Patients were stratified by severity and treated with various immunomodulatory regimens, including IVIG+MP, IVIG+MP+anakinra, and IVIG+MP+anakinra+TPE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with mild disease and low inflammatory markers (median CRP 9\u2009mg\/dL, ferritin 192\u2009\u00b5g\/dL) received IVIG+MP. Those with higher inflammation (CRP 20\u201324\u2009mg\/dL, ferritin 308\u2013846\u2009\u00b5g\/dL) without cardio-pulmonary support were treated with IVIG+low-dose-MP+anakinra. Patients with shock, macrophage activation syndrome, or bicytopenia received IVIG+high-dose-MP+anakinra. TPE was added in cases requiring cardio-pulmonary support. Most were discharged without corticosteroids or anakinra; only 11% received a short outpatient prednisolone taper.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The mid-term longitudinal assessment of MIS-C patients suggests that timely immunomodulatory therapies, guided by laboratory parameters, promote safe resolution of systemic inflammation and cardiac complications, and shorten treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Demonstrates that short-term, biomarker-guided use of anakinra and corticosteroids effectively controls hyperinflammation in MIS-C.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Highlights that prolonged corticosteroid therapy may not be necessary, even in severe cases.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Provides evidence of early cardiac recovery, including resolution of CAAs, without post-discharge steroids.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Supports a steroid-sparing treatment approach, reducing risks of long-term immunosuppression.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>May inform future MIS-C treatment guidelines by minimizing the need for escalation therapy, ECMO, and related complications.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-025-04706-6","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:15:19Z","timestamp":1768076119000},"page":"765-775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multisystem Inflammatory Syndrome in Children with tailored therapy and six-month outcome"],"prefix":"10.1038","volume":"100","author":[{"given":"Osman Oguz","family":"Demir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kubra","family":"Aykac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Hoi Hin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selman","family":"Kesici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Hakan","family":"Aykan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelda","family":"Bilginer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Bulent","family":"Cengiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae S. M.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Ozsurekci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"4706_CR1","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(20)31094-1","volume":"395","author":"S Riphagen","year":"2020","unstructured":"Riphagen, S., Gomez, X., Gonzalez-Martinez, C., Wilkinson, N. & Theocharis, P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395, 1607\u20131608 (2020).","journal-title":"Lancet"},{"key":"4706_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jama.2020.10369","volume":"324","author":"E Whittaker","year":"2020","unstructured":"Whittaker, E. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 324, 259\u2013269 (2020).","journal-title":"JAMA"},{"key":"4706_CR3","unstructured":"Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). https:\/\/emergency.cdc.gov\/han\/2020\/han00432.asp (2020)."},{"key":"4706_CR4","unstructured":"World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Scientific brief, 15 May 2020. Geneva, Switzerland: WHO; Available from: https:\/\/iris.who.int\/handle\/10665\/332095 (2020)."},{"key":"4706_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1161\/CIRCULATIONAHA.120.048360","volume":"142","author":"Z Belhadjer","year":"2020","unstructured":"Belhadjer, Z. et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation 142, 429\u2013436 (2020).","journal-title":"Circulation"},{"key":"4706_CR6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/jama.2021.2091","volume":"325","author":"LR Feldstein","year":"2021","unstructured":"Feldstein, L. R. et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 325, 1074\u20131087 (2021).","journal-title":"JAMA"},{"key":"4706_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/antibiotics12020234","volume":"12","author":"T Karampatakis","year":"2023","unstructured":"Karampatakis, T., Tsergouli, K. & Behzadi, P. Carbapenem-Resistant Klebsiella pneumoniae: virulence factors, molecular epidemiology and latest updates in treatment options. Antibiotics 12, 234 (2023).","journal-title":"Antibiotics"},{"key":"4706_CR8","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle, B. W. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135, e927\u2013e999 (2017).","journal-title":"Circulation"},{"key":"4706_CR9","doi-asserted-by":"crossref","unstructured":"Hothorn, T., Hornik, K., & Zeileis, A. Unbiased Recursive Partitioning: A Conditional Inference Framework. J. Comput. Graph. Stat., 15, 651\u2013674 (2006).","DOI":"10.1198\/106186006X133933"},{"key":"4706_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S2352-4642(23)00078-0","volume":"7","author":"V Piechotta","year":"2023","unstructured":"Piechotta, V. et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis. Lancet Child Adolesc. Health 7, 379\u2013391 (2023).","journal-title":"Lancet Child Adolesc. Health"},{"key":"4706_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jpeds.2022.02.046","volume":"245","author":"P Yavuz","year":"2022","unstructured":"Yavuz, P. et al. New-onset ocular myasthenia after multisystem inflammatory syndrome in children. J. Pediatr. 245, 213\u2013216 (2022).","journal-title":"J. Pediatr."},{"key":"4706_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/art.41481","volume":"73","author":"I Kone-Paut","year":"2021","unstructured":"Kone-Paut, I. et al. Phase II open label study of anakinra in intravenous immunoglobulin-resistant Kawasaki disease. Arthritis Rheumatol. 73, 151\u2013161 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"4706_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1161\/ATVBAHA.119.313863","volume":"40","author":"RA Porritt","year":"2020","unstructured":"Porritt, R. A. et al. Interleukin-1 beta-mediated sex differences in Kawasaki disease vasculitis development and response to treatment. Arterioscler. Thromb. Vasc. Biol. 40, 802\u2013818 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"4706_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","volume":"71","author":"NM Ter Haar","year":"2019","unstructured":"Ter Haar, N. M. et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol. 71, 1163\u20131173 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"4706_CR15","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","volume":"27","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou, E. et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat. Med. 27, 1752\u20131760 (2021).","journal-title":"Nat. Med."},{"key":"4706_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12969-023-00858-z","volume":"21","author":"BLP Dizon","year":"2023","unstructured":"Dizon, B. L. P. et al. Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study. Pediatr. Rheumatol. Online J. 21, 76 (2023).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"4706_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/rheumatology\/kead381","volume":"63","author":"A Taddio","year":"2024","unstructured":"Taddio, A. et al. Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children, regardless of disease severity. Rheumatology 63, 366\u2013375 (2024).","journal-title":"Rheumatology"},{"key":"4706_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.942455","volume":"10","author":"S Caglayan","year":"2022","unstructured":"Caglayan, S. et al. Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19. Front. Pediatr. 10, 942455 (2022).","journal-title":"Front. Pediatr."},{"key":"4706_CR19","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/art.41454","volume":"72","author":"LA Henderson","year":"2020","unstructured":"Henderson, L. A. et al. American College of Rheumatology Clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol. 72, 1791\u20131805 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"4706_CR20","doi-asserted-by":"publisher","first-page":"102212","DOI":"10.1016\/j.eclinm.2023.102212","volume":"64","author":"F Sperotto","year":"2023","unstructured":"Sperotto, F. et al. Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium. eClinicalMedicine 64, 102212 (2023).","journal-title":"eClinicalMedicine"},{"key":"4706_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/art.42062","volume":"74","author":"LA Henderson","year":"2022","unstructured":"Henderson, L. A. et al. American College of Rheumatology Clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. Arthritis Rheumatol. 74, e1\u2013e20 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"4706_CR22","doi-asserted-by":"publisher","first-page":"e2021051155","DOI":"10.1542\/peds.2021-051155","volume":"148","author":"KM Farooqi","year":"2021","unstructured":"Farooqi, K. M. et al. Longitudinal outcomes for multisystem inflammatory syndrome in children. Pediatrics 148, e2021051155 (2021).","journal-title":"Pediatrics"},{"key":"4706_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1017\/S1047951121003024","volume":"32","author":"AS Harahsheh","year":"2022","unstructured":"Harahsheh, A. S. et al. Cardiac echocardiogram findings of severe acute respiratory syndrome coronavirus-2-associated multi-system inflammatory syndrome in children. Cardiol. Young-. 32, 718\u2013726 (2022).","journal-title":"Cardiol. Young-."},{"key":"4706_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12969-023-00924-6","volume":"21","author":"EB Akkoyun","year":"2023","unstructured":"Akkoyun, E. B. et al. Impact of anakinra use on clinical outcomes in children with moderate or severe multisystem inflammatory syndrome in children: a propensity score matched retrospective cohort study. Pediatr. Rheumatol. Online J. 21, 141 (2023).","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"4706_CR25","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/art.42495","volume":"75","author":"JC Chang","year":"2023","unstructured":"Chang, J. C. et al. Variation in early anakinra use and short-term outcomes in multisystem inflammatory syndrome in children. Arthritis Rheumatol. 75, 1466\u20131476 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"4706_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S2352-4642(21)00138-3","volume":"5","author":"J Penner","year":"2021","unstructured":"Penner, J. et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc. Health 5, 473\u2013482 (2021).","journal-title":"Lancet Child Adolesc. Health"},{"key":"4706_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.41622","volume":"5","author":"MBF Son","year":"2022","unstructured":"Son, M. B. F. et al. Postdischarge glucocorticoid use and clinical outcomes of multisystem inflammatory syndrome in children. JAMA Netw. Open 5, e2241622 (2022).","journal-title":"JAMA Netw. Open"},{"key":"4706_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jama.2021.0694","volume":"325","author":"N Ouldali","year":"2021","unstructured":"Ouldali, N. et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 325, 855\u2013864 (2021).","journal-title":"JAMA"},{"key":"4706_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa2102605","volume":"385","author":"MBF Son","year":"2021","unstructured":"Son, M. B. F. et al. Multisystem inflammatory syndrome in children - initial therapy and outcomes. N. Engl. J. Med. 385, 23\u201334 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4706_CR30","doi-asserted-by":"publisher","first-page":"e2021050973","DOI":"10.1542\/peds.2021-050973","volume":"148","author":"CA Capone","year":"2021","unstructured":"Capone, C. A. et al. Six month follow-up of patients with multi-system inflammatory syndrome in children. Pediatrics 148, e2021050973 (2021).","journal-title":"Pediatrics"},{"key":"4706_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/v15010094","volume":"15","author":"DD Reiff","year":"2022","unstructured":"Reiff, D. D. & Cron, R. Q. Timely resolution of SARS-CoV-2-related multi-system inflammatory syndrome in children. Viruses 15, 94 (2022).","journal-title":"Viruses"},{"key":"4706_CR32","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","volume":"379","author":"T Kobayashi","year":"2012","unstructured":"Kobayashi, T. et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 379, 1613\u20131620 (2012).","journal-title":"Lancet"},{"key":"4706_CR33","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/jpc.16408","volume":"59","author":"SM McGlacken-Byrne","year":"2023","unstructured":"McGlacken-Byrne, S. M., Johnson, M., Penner, J., du Pre, P. & Katugampola, H. Characterising approaches to steroid therapy in paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2. J. Paediatr. Child Health 59, 890\u2013894 (2023).","journal-title":"J. Paediatr. Child Health"},{"key":"4706_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1442-200X.2011.03487.x","volume":"54","author":"T Hokosaki","year":"2012","unstructured":"Hokosaki, T. et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr. Int. 54, 99\u2013103 (2012).","journal-title":"Pediatr. Int."},{"key":"4706_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cyto.2014.07.003","volume":"70","author":"T Fujimaru","year":"2014","unstructured":"Fujimaru, T. et al. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange. Cytokine 70, 156\u2013160 (2014).","journal-title":"Cytokine"},{"key":"4706_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152043","volume":"55","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Efficacy of plasma exchange on top of standard immunosuppressive therapy in adult autoimmune inflammatory rheumatic diseases-associated macrophage activation syndrome, a single center real-world analysis. Semin. Arthritis Rheum. 55, 152043 (2022).","journal-title":"Semin. Arthritis Rheum."},{"key":"4706_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2220-9","volume":"22","author":"H Knaup","year":"2018","unstructured":"Knaup, H. et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit. Care 22, 285 (2018).","journal-title":"Crit. Care"},{"key":"4706_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2021.103119","volume":"60","author":"S Emeksiz","year":"2021","unstructured":"Emeksiz, S. et al. Therapeutic plasma exchange: a potential management strategy for critically ill MIS-C patients in the pediatric intensive care unit. Transfus. Apher. Sci. 60, 103119 (2021).","journal-title":"Transfus. Apher. Sci."},{"key":"4706_CR39","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/jca.21971","volume":"37","author":"B Katlan","year":"2022","unstructured":"Katlan, B. et al. Early is superior to late plasma exchange for severe multisystem inflammatory syndrome in children. J. Clin. Apher. 37, 281\u2013291 (2022).","journal-title":"J. Clin. Apher."},{"key":"4706_CR40","doi-asserted-by":"publisher","first-page":"e1350","DOI":"10.1097\/CCM.0000000000004613","volume":"48","author":"J Fernandez","year":"2020","unstructured":"Fernandez, J. et al. Plasma exchange: an effective rescue therapy in critically ill patients with coronavirus disease 2019 infection. Crit. Care Med. 48, e1350\u2013e1355 (2020).","journal-title":"Crit. Care Med."},{"key":"4706_CR41","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00431-021-03993-5","volume":"180","author":"L Hoste","year":"2021","unstructured":"Hoste, L., Van Paemel, R. & Haerynck, F. Multisystem inflammatory syndrome in children related to COVID-19: a systematic review. Eur. J. Pediatr. 180, 2019\u20132034 (2021).","journal-title":"Eur. J. Pediatr."},{"key":"4706_CR42","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.cjco.2020.09.004","volume":"2","author":"MD Elias","year":"2020","unstructured":"Elias, M. D. et al. Management of multisystem inflammatory syndrome in children associated with COVID-19: a survey from the International Kawasaki Disease Registry. CJC Open 2, 632\u2013640 (2020).","journal-title":"CJC Open"},{"key":"4706_CR43","doi-asserted-by":"publisher","first-page":"e151520","DOI":"10.1172\/JCI151520","volume":"131","author":"RA Porritt","year":"2021","unstructured":"Porritt, R. A. et al. The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. J. Clin. Invest. 131, e151520 (2021).","journal-title":"J. Clin. Invest."},{"key":"4706_CR44","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/jth.15340","volume":"19","author":"M Al-Ghafry","year":"2021","unstructured":"Al-Ghafry, M. et al. Multisystem inflammatory syndrome in children (MIS-C) and the prothrombotic state: Coagulation profiles and rotational thromboelastometry in a MIS-C cohort. J. Thromb. Haemost. 19, 1764\u20131770 (2021).","journal-title":"J. Thromb. Haemost."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04706-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04706-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04706-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:32:24Z","timestamp":1791210744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04706-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4706"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-04706-6","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}